370 related articles for article (PubMed ID: 28203752)
21. BRAF mutation in endometrial carcinoma and hyperplasia: correlation with KRAS and p53 mutations and mismatch repair protein expression.
Feng YZ; Shiozawa T; Miyamoto T; Kashima H; Kurai M; Suzuki A; Konishi I
Clin Cancer Res; 2005 Sep; 11(17):6133-8. PubMed ID: 16144912
[TBL] [Abstract][Full Text] [Related]
22. [Dualistic model of molecular pathogenesis in endometrial carcinoma].
Lax SF
Zentralbl Gynakol; 2002 Jan; 124(1):10-6. PubMed ID: 11873308
[TBL] [Abstract][Full Text] [Related]
23. Theories of endometrial carcinogenesis: a multidisciplinary approach.
Sherman ME
Mod Pathol; 2000 Mar; 13(3):295-308. PubMed ID: 10757340
[TBL] [Abstract][Full Text] [Related]
24. Mutational profile of endometrial hyperplasia and risk of progression to endometrioid adenocarcinoma.
Russo M; Newell JM; Budurlean L; Houser KR; Sheldon K; Kesterson J; Phaeton R; Hossler C; Rosenberg J; DeGraff D; Shuman L; Broach JR; Warrick JI
Cancer; 2020 Jun; 126(12):2775-2783. PubMed ID: 32187665
[TBL] [Abstract][Full Text] [Related]
25. Laminin C1 expression by uterine carcinoma cells is associated with tumor progression.
Kashima H; Wu RC; Wang Y; Sinno AK; Miyamoto T; Shiozawa T; Wang TL; Fader AN; Shih IeM
Gynecol Oncol; 2015 Nov; 139(2):338-44. PubMed ID: 26343160
[TBL] [Abstract][Full Text] [Related]
26. [Pitfalls in the histopathological diagnostics of endometrial carcinoma and its precursors : Clinically relevant differential diagnoses, avoidance of false positive diagnoses].
Kommoss F; Lax SF
Pathologe; 2016 Nov; 37(6):512-520. PubMed ID: 27681950
[TBL] [Abstract][Full Text] [Related]
27. Prognostic aspects on endometrial hyperplasia and neoplasia.
Sivridis E; Giatromanolaki A
Virchows Arch; 2001 Aug; 439(2):118-26. PubMed ID: 11561751
[TBL] [Abstract][Full Text] [Related]
28. Quantitative next-generation sequencing-based analysis indicates progressive accumulation of microsatellite instability between atypical hyperplasia/endometrial intraepithelial neoplasia and paired endometrioid endometrial carcinoma.
Chapel DB; Patil SA; Plagov A; Puranik R; Mendybaeva A; Steinhardt G; Wanjari P; Lastra RR; Kadri S; Segal JP; Ritterhouse LL
Mod Pathol; 2019 Oct; 32(10):1508-1520. PubMed ID: 31186530
[TBL] [Abstract][Full Text] [Related]
29. Mutations of the KRAS oncogene in endometrial hyperplasia and carcinoma.
Dobrzycka B; Terlikowski SJ; Mazurek A; Kowalczuk O; Niklińska W; Chyczewski L; Kulikowski M
Folia Histochem Cytobiol; 2009; 47(1):65-8. PubMed ID: 19419940
[TBL] [Abstract][Full Text] [Related]
30. Expression of cyclin D1 in normal, metaplastic, hyperplastic endometrium and endometrioid carcinoma suggests a role in endometrial carcinogenesis.
Ruhul Quddus M; Latkovich P; Castellani WJ; James Sung C; Steinhoff MM; Briggs RC; Miranda RN
Arch Pathol Lab Med; 2002 Apr; 126(4):459-63. PubMed ID: 11900573
[TBL] [Abstract][Full Text] [Related]
31. [Expression of beta-catenin, Glut-1, PTEN proteins in uterine endometrioid adenocarcinoma and its precursor lesions].
Xiong Y; Xiong YY; Zhou YF
Zhonghua Bing Li Xue Za Zhi; 2009 Sep; 38(9):594-9. PubMed ID: 20079187
[TBL] [Abstract][Full Text] [Related]
32. POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium.
Meng B; Hoang LN; McIntyre JB; Duggan MA; Nelson GS; Lee CH; Köbel M
Gynecol Oncol; 2014 Jul; 134(1):15-9. PubMed ID: 24844595
[TBL] [Abstract][Full Text] [Related]
33. RASSF1A methylation and K-ras and B-raf mutations and recurrent endometrial cancer.
Pijnenborg JM; Dam-de Veen GC; Kisters N; Delvoux B; van Engeland M; Herman JG; Groothuis PG
Ann Oncol; 2007 Mar; 18(3):491-7. PubMed ID: 17170014
[TBL] [Abstract][Full Text] [Related]
34. Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation.
Ambros RA; Sherman ME; Zahn CM; Bitterman P; Kurman RJ
Hum Pathol; 1995 Nov; 26(11):1260-7. PubMed ID: 7590702
[TBL] [Abstract][Full Text] [Related]
35. PIKing the type and pattern of PI3K pathway mutations in endometrioid endometrial carcinomas.
Marchiò C; De Filippo MR; Ng CK; Piscuoglio S; Soslow RA; Reis-Filho JS; Weigelt B
Gynecol Oncol; 2015 May; 137(2):321-8. PubMed ID: 25701704
[TBL] [Abstract][Full Text] [Related]
36. Mutual exclusiveness between PIK3CA and KRAS mutations in endometrial carcinoma.
Kang S; Seo SS; Chang HJ; Yoo CW; Park SY; Dong SM
Int J Gynecol Cancer; 2008; 18(6):1339-43. PubMed ID: 18221484
[TBL] [Abstract][Full Text] [Related]
37. Expression of tumor suppressor gene product p14ARF in endometrioid adenocarcinoma of the uterine corpus.
Watanabe J; Nishizaki R; Jobo T; Kamata Y; Hata H; Nishimura Y; Fujisawa T; Okayasu I; Kuramoto H
Int J Gynecol Pathol; 2004 Jul; 23(3):234-40. PubMed ID: 15213599
[TBL] [Abstract][Full Text] [Related]
38. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses.
Lax SF; Kurman RJ
Verh Dtsch Ges Pathol; 1997; 81():228-32. PubMed ID: 9474874
[TBL] [Abstract][Full Text] [Related]
39. Strong correlation between molecular changes in endometrial carcinomas and concomitant hyperplasia.
Zauber P; Denehy TR; Taylor RR; Ongcapin EH; Marotta S; Sabbath-Solitare M
Int J Gynecol Cancer; 2015 Jun; 25(5):863-8. PubMed ID: 25768080
[TBL] [Abstract][Full Text] [Related]
40. Cellular retinol binding protein-1 expression in endometrial hyperplasia and carcinoma: diagnostic and possible therapeutic implications.
Orlandi A; Ferlosio A; Ciucci A; Francesconi A; Lifschitz-Mercer B; Gabbiani G; Spagnoli LG; Czernobilsky B
Mod Pathol; 2006 Jun; 19(6):797-803. PubMed ID: 16575402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]